Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Avoiding neurotoxicity with lithium-carbamazepine combinations.

J McGinness1, A Kishimoto, L E Hollister

  • 1Harris County Psychiatric Center, Unit 1B, Houston, TX 77021.

Psychopharmacology Bulletin
|January 1, 1990
PubMed
Summary

Carbamazepine (CBZ) and lithium show therapeutic synergy but raise neurotoxicity concerns. This study found no evidence of synergistic neurotoxicity when combining these psychiatric medications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Abrogation of protein phosphatase 6 promotes skin carcinogenesis induced by DMBA.

Oncogene·2014
Same author

The expressions of claudin-1 and E-cadherin in junctional epithelium.

Journal of periodontal research·2010
Same author

Irsogladine maleate abolishes the increase in interleukin-8 levels caused by outer membrane protein 29 from Aggregatibacter (Actinobacillus) actinomycetemcomitans through the ERK pathway in human gingival epithelial cells.

Journal of periodontal research·2008
Same author

Irsogladine maleate counters the interleukin-1 beta-induced suppression in gap-junctional intercellular communication but does not affect the interleukin-1 beta-induced zonula occludens protein-1 levels in human gingival epithelial cells.

Journal of periodontal research·2008
Same author

Neuronal DNA damage correlates with overexpression of interleukin-1beta converting enzyme in APPV717F mice.

Neurobiology of aging·2002
Same author

[Refractory idiopathic cold agglutinin disease successfully treated with intermittent high-dose cyclophosphamide].

[Rinsho ketsueki] The Japanese journal of clinical hematology·2001

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Carbamazepine (CBZ) and lithium are used therapeutically, often in combination for treatment-resistant patients.
  • Both CBZ and lithium are known to cause neurotoxicity, raising safety concerns when co-administered.
  • Established safe serum levels for individual drugs do not directly translate to combined use.

Purpose of the Study:

  • To investigate the potential for synergistic neurotoxicity when combining carbamazepine and lithium.
  • To quantitatively determine the safe serum level range for combined CBZ and lithium therapy.

Main Methods:

  • Paired serum levels of carbamazepine and lithium were plotted on a two-dimensional graph.
  • The region associated with neurotoxicity was quantitatively identified.

Related Experiment Videos

Main Results:

  • Analysis of the plotted data revealed no evidence of synergistic neurotoxicity.
  • The study identified a specific region on the graph where neurotoxicity begins to occur.

Conclusions:

  • Combining carbamazepine and lithium does not appear to increase the risk of neurotoxicity synergistically.
  • Further research may refine safe dosing guidelines for combined therapy based on these findings.